Laura Spiers Selected Research

NUC-1031

1/2021	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
10/2018	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Spiers Research Topics

Disease

5	Neoplasms (Cancer) 07/2023 - 10/2018
3	Hyperthermia 09/2023 - 12/2022
1	Adenocarcinoma 09/2023
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Fatigue 10/2018
1	Bites and Stings (Sting) 01/2017

Drug/Important Bio-Agent (IBA)

2	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2023 - 12/2022
2	Liposomes (Liposome)IBA 09/2023 - 12/2022
2	NUC-1031IBA 01/2021 - 10/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	PlatinumIBA 01/2021
1	AntibodiesIBA 10/2020
1	Programmed Cell Death 1 ReceptorIBA 10/2020
1	Gemcitabine FDA Link 10/2018
1	ProTidesIBA 10/2018
1	phosphoramidic acidIBA 10/2018
1	Epithelial Cell Adhesion MoleculeIBA 01/2017

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 09/2023 - 01/2021
2	Therapeutics 07/2023 - 12/2019
1	Induced Hyperthermia (Thermotherapy) 09/2023
1	Ultrasonic Therapy 07/2023
1	Immunotherapy 12/2019